Zacks Investment Research Lowers Supernus Pharmaceuticals, Inc. (SUPN) to Hold

Zacks Investment Research lowered shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) from a strong-buy rating to a hold rating in a research note issued to investors on Friday morning.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Several other equities analysts have also recently issued reports on SUPN. Janney Montgomery Scott initiated coverage on Supernus Pharmaceuticals in a report on Friday, July 14th. They issued a neutral rating and a $47.00 price target on the stock. Piper Jaffray Companies cut Supernus Pharmaceuticals from an overweight rating to a neutral rating and set a $46.00 price target on the stock. in a report on Monday, July 17th. Stifel Nicolaus reiterated a buy rating and issued a $47.00 price target (up previously from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. BidaskClub cut Supernus Pharmaceuticals from a strong-buy rating to a buy rating in a report on Tuesday, July 25th. Finally, Cowen and Company reiterated a positive rating and issued a $50.00 price target (up previously from $40.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 3rd. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $49.60.

Shares of Supernus Pharmaceuticals (SUPN) opened at $37.50 on Friday. The company has a market capitalization of $1,909.51, a price-to-earnings ratio of 35.14, a PEG ratio of 1.58 and a beta of 1.30. Supernus Pharmaceuticals has a 1-year low of $20.55 and a 1-year high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The company had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company’s revenue was up 41.5% compared to the same quarter last year. equities analysts forecast that Supernus Pharmaceuticals will post 1.08 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was published by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/zacks-investment-research-lowers-supernus-pharmaceuticals-inc-supn-to-hold/1774921.html.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 50,000 shares of the firm’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $47.60, for a total transaction of $2,380,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $45.23, for a total value of $167,758.07. Following the transaction, the vice president now owns 17,500 shares in the company, valued at approximately $791,525. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 153,709 shares of company stock worth $7,223,108. Company insiders own 6.70% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Pinebridge Investments L.P. boosted its holdings in Supernus Pharmaceuticals by 1.3% during the second quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock worth $285,000 after buying an additional 86 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in Supernus Pharmaceuticals by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 20,500 shares of the specialty pharmaceutical company’s stock worth $884,000 after buying an additional 100 shares during the last quarter. Arizona State Retirement System boosted its holdings in Supernus Pharmaceuticals by 0.4% during the second quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after buying an additional 100 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Supernus Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock worth $1,579,000 after buying an additional 128 shares during the last quarter. Finally, CS Mckee LP boosted its holdings in Supernus Pharmaceuticals by 0.5% during the second quarter. CS Mckee LP now owns 42,050 shares of the specialty pharmaceutical company’s stock worth $1,812,000 after buying an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 96.45% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Brandon Morrow Becomes Hot Commodity
Brandon Morrow Becomes Hot Commodity


Leave a Reply

 
© 2006-2017 BBNS.